3rd Quarter - Report

MUSCULAR DYSTROPHY ASSOCIATION, INC. for MUSCULAR DYSTROPHY ASSOCIATION, INC.

Firm
Client
Income
—
Expenses
$60,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Aviation/Airlines/Airports AVI

Advocated for access to air travel for individuals with neuromuscular conditions by advocating for ongoing implementation of the Air Carrier Access Act (ACAA) and the Federal Aviation Administration Reauthorization Act of 2017. Advocated for passage of the Air Carrier Access Amendments Act (S. 669, H.R. 1549).

LobbyistCovered position, as disclosed
BRITTANY JOHNSON HERNANDEZ —

Contacted: SENATE; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Federal Aviation Administration (FAA); Transportation, Dept of (DOT)

Bills named: S. 669 (116th), H.R. 1549 (116th)

Medicare/Medicaid MMM

Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Cited opposition to the expansion of Section 1115 demonstration waivers that would create substantial barriers to care for patients and families who enroll in Medicaid.

LobbyistCovered position, as disclosed
BRITTANY JOHNSON HERNANDEZ —

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Federal Aviation Administration (FAA); Transportation, Dept of (DOT); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE; Food & Drug Administration (FDA)

Budget/Appropriations BUD

Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention.

LobbyistCovered position, as disclosed
BRITTANY JOHNSON HERNANDEZ —
PAUL MELMEYER —

Contacted: Transportation, Dept of (DOT); SENATE; Federal Aviation Administration (FAA); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH)

Medical/Disease Research/Clinical Labs MED

Advocated in favor of robust appropriations funding for the National Institutes of Health, the Food and Drug Administration, the Health Resources and Services Administration, and the Centers for Disease Control and Prevention.

LobbyistCovered position, as disclosed
BRITTANY JOHNSON HERNANDEZ —
PAUL MELMEYER —

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Transportation, Dept of (DOT); Federal Aviation Administration (FAA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Health care issues affecting individuals with neuromuscular disease including therapy development, newborn screening, adequate insurance coverage, and access to care. Advocated for the passage of the Newborn Screening Saves Lives Reauthorization Act, H.R. 2507 / S. 2158, to encourage investment in the national newborn screening program in order to detect more neuromuscular conditions early to speed appropriate interventions for patients. Advocated for increased funding for National Institutes of Health, Food and Drug Administration, Health Resources and Services Administration, and other health agencies that conduct research on neuromuscular disease and provide services to those with these conditions. Advocated for adequate, affordable, accessible health coverage for individuals with neuromuscular conditions. Cited opposition to the expansion of Section 1115 demonstration waivers that would create substantial barriers to care for patients and families who enroll in Medicaid. Advocated in opposition to proposed action on the part of the Office of Management and Budget to amend the federal poverty measure in a manner that may impact the ability of individuals with neuromuscular disease and their caregivers to access necessary safety-net supports such as Medicaid, state health programs, and other services. Advocated in favor of activities to improve outreach and enrollment for individuals to who acquire health insurance on the individual marketplace including: (1) a provision added to H.R. 987 that would require the Department of Health and Human Services to resume activities related to outreach and educational activities for open enrollment; and (2) H.R.1386, Expand Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act of 2019. Advocated for passage of H.R. 986, the Protecting Americans with Preexisting Conditions Act of 2019, which would require the Administration to rescind its Section 1332 State Relief and Empowerment Waivers Guidance, released on October 22, 2018 (1332 guidance). The guidance would allow states to let individuals use advanced premium tax credits to purchase non-compliant short-term, limited duration insurance plans-which could further draw younger, healthier people out of the risk pool for comprehensive insurance and drive up premiums for those who need comprehensive coverage, such as individuals with neuromuscular conditions. Also advocated for the passage of H.R. 1010, legislation to provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect. Advocated maintaining strong incentives for rare disease drug development included within the Orphan Drug Act (PL 97-414) Advocated for the continuance of the Rare Pediatric Disease Priority Review Voucher Program within the context of the Creating Hope Reauthorization Act (H.R.4439)

LobbyistCovered position, as disclosed
BRITTANY JOHNSON HERNANDEZ —
PAUL MELMEYER —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Transportation, Dept of (DOT); SENATE; Federal Aviation Administration (FAA); Natl Institutes of Health (NIH); Office of Management & Budget (OMB)

Bills named: H.R. 987 (116th), H.R. 1386 (116th), H.R. 4439 (116th), H.R. 1010 (116th), H.R. 986 (116th), S. 2158 (116th), H.R. 2507 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.